InMed Pharmaceuticals(FRA) MWG2

Market CapN/A

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

N/A

InMed Pharmaceuticals Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$2.81

Net Income (TTM)

-$7.18

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

MWG2 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

MWG2 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

InMed Pharmaceuticals Performance Analysis

InMed Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-06-30	USD 967,399	N/A
2023	2023-06-30	USD 3,955,317	308.9%
2024	2024-06-30	USD 4,251,841	7.5%
2025	2025-06-30	USD 4,546,001	6.9%

InMed Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-06-30	USD -14,725.14	N/A
2023	2023-06-30	USD -62.09	-99.6%
2024	2024-06-30	USD -18.63	-70.0%
2025	2025-06-30	USD -7.69	-58.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

+0.0%

Gross Profit

-$0.12

-2.6%

Gross Margin

3.19%

+0.1%

Market Cap

N/A

Market Cap/Employee

$0.01

N/A

Employees

N/A

Net Income

-$2.39

+1.2%

EBITDA

-$2.29

+1.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$4.84

-5.4%

Total Debt

$0.36

+0.5%

Accounts Receivable

$0.16

+0.6%

Inventory

$0.00

+0.0%

Long Term Debt

$0.03

+0.1%

Short Term Debt

$0.34

+0.9%

Return on Assets

-86.99%

+1.2%

Return on Invested Capital

N/A

Free Cash Flow

-$1.49

+1.0%

Operating Cash Flow

-$1.49

+1.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.92+0.00%

WETOWetour Robotics

WETOWetour Robotics$5.48-0.04%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.67+0.02%

NVDANvidia

NVDANvidia$220.78+0.01%

INTCIntel

INTCIntel$89.51+0.00%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

Questions About MWG2

What is the current price of InMed Pharmaceuticals?

InMed Pharmaceuticals is trading at N/A per share.

What is the 52-week range for InMed Pharmaceuticals?

Over the past 52 weeks, InMed Pharmaceuticals has traded between N/A and N/A.

How much debt does InMed Pharmaceuticals have?

As of the most recent reporting period, InMed Pharmaceuticals reported total debt of $364.65K.

How much cash does InMed Pharmaceuticals have on hand?

InMed Pharmaceuticals reported $4.48M in cash and cash equivalents in its most recent financial results.

What is InMed Pharmaceuticals’s dividend yield?

InMed Pharmaceuticals does not currently have a dividend yield.

InMed Pharmaceuticals(FRA) MWG2

InMed Pharmaceuticals Financials at a Glance

MWG2 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

MWG2 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

InMed Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MWG2

What is the current price of InMed Pharmaceuticals?

What is the 52-week range for InMed Pharmaceuticals?

How much debt does InMed Pharmaceuticals have?

How much cash does InMed Pharmaceuticals have on hand?

What is InMed Pharmaceuticals’s dividend yield?

Premium Investing Services